Glenn Mattes's Insider Trades & SAST Disclosures
Glenn Mattes's most recent trade in Tff Pharmaceuticals Inc was a trade of 16,000 Common Stock done at an average price of $4.8 . Disclosure was reported to the exchange on May 16, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Glenn Mattes.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 4.78 per share. | 16 May 2022 | 16,000 | 36,000 (0%) | 0% | 4.8 | 76,480 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 7.10 per share. | 16 Sep 2021 | 10,000 | 20,000 (0%) | 0% | 7.1 | 71,000 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 15 Mar 2021 | 50,000 | 10,000 (0%) | 0% | 17.0 | 852,000 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 50,000 | 944,227 | - | - | Stock Options (Right to Buy) | |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 15 Mar 2021 | 50,000 | 60,000 (0%) | 0% | 2.5 | 125,000 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 16 Feb 2021 | 40,000 | 50,000 (0%) | 0% | 2.5 | 100,000 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 40,000 | 994,227 | - | - | Stock Options (Right to Buy) | |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.82 per share. | 16 Feb 2021 | 40,000 | 10,000 (0%) | 0% | 16.8 | 672,800 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.33 per share. | 23 Dec 2020 | 30,000 | 10,000 (0%) | 0% | 15.3 | 459,900 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2020 | 30,000 | 1,074,227 | - | - | Stock Options (Right to Buy) | |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 23 Dec 2020 | 30,000 | 40,000 (0%) | 0% | 2.5 | 75,000 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 10 Nov 2020 | 108,830 | 10,000 (0%) | 0% | 15.0 | 1,631,906 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 10 Nov 2020 | 108,830 | 118,830 (0%) | 0% | 2.5 | 272,075 | Common Stock |
| Tff Pharmaceuticals Inc | Glenn Mattes | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2020 | 108,830 | 1,104,227 | - | - | Stock Options (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges